Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.
Your view on ARMP
Overview
What the company does, where it operates, and who runs it.
About Armata Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Deborah L. Birx
- Headquarters
- 4503 Glencoe Avenue, Marina del Rey, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Deborah L. Birx
- Headquarters
- 4503 Glencoe Avenue, Marina del Rey, CA, US
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology.
The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Marina del Rey, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Armata Pharmaceuticals, Inc., and the rating behind it. ARMP last traded at $5.38; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Armata Pharmaceuticals, Inc.. Starting points for Armata Pharmaceuticals, Inc.: EPS -$5.23, beta 1.35 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Armata Pharmaceuticals, Inc.. Armata Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Armata Pharmaceuticals, Inc.. Trailing twelve-month EPS for Armata Pharmaceuticals, Inc. stands at -$5.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Armata Pharmaceuticals, Inc.. Armata Pharmaceuticals, Inc. has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Armata Pharmaceuticals, Inc. valued side by side against its closest peers. Armata Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Armata Pharmaceuticals, Inc., and how their positions are changing. At a $197.5M market value, institutional positions materially move Armata Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Armata Pharmaceuticals, Inc. executives and directors. Shares of Armata Pharmaceuticals, Inc. have traded between $0.90 and $16.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Armata Pharmaceuticals, Inc.. Armata Pharmaceuticals, Inc. is a $197.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Armata Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Armata Pharmaceuticals, Inc.. Coverage tracks Armata Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.